1 recruiting, 1 withdrawn. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Heterotopic Ossification (HO): new trials by email Literature Review of Heterotopic Ossification (HO) trials Research Report on Heterotopic Ossification (HO)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. Andecaliximab - Heterotopic Ossification (HO) | Phase 1 / Phase 2 | Recruiting | Ashibio Inc | 10 | 2025-05-14 | 2025-06-17 |
| Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) garetosmab - Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO) | Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2021-10-13 | 2021-11-01 |
Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
andecaliximab (1)
Ashibio Inc (1) · Regeneron Pharmaceuticals (1)
United States (1)
Andrew Park, MD (1)